These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32296041)

  • 1. The identification of a CD47-blocking "hotspot" and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination.
    Shi R; Chai Y; Duan X; Bi X; Huang Q; Wang Q; Tan S; Gao GF; Zhu J; Yan J
    Signal Transduct Target Ther; 2020 Mar; 5(1):16. PubMed ID: 32296041
    [No Abstract]   [Full Text] [Related]  

  • 2. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells.
    Lian S; Xie R; Ye Y; Lu Y; Cheng Y; Xie X; Li S; Jia L
    Sci Rep; 2019 Mar; 9(1):4532. PubMed ID: 30872703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1.
    Malinge P; Chauchet X; Bourguignon J; Bosson N; Calloud S; Bautzova T; Borlet M; Laursen M; Kelpsas V; Rose N; Gueneau F; Ravn U; Magistrelli G; Fischer N
    MAbs; 2024; 16(1):2362432. PubMed ID: 38849989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective CD47 targeting with a bispecific antibody.
    Ferlin W; Masternak K; Shang L
    Cancer Immunol Immunother; 2021 Apr; 70(4):1161-1162. PubMed ID: 33388996
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune Checkpoint-Associated Locations of Diffuse Gliomas Comparing Pediatric With Adult Patients Based on Voxel-Wise Analysis.
    Zhang L; Zhang B; Dou Z; Wu J; Iranmanesh Y; Jiang B; Sun C; Zhang J
    Front Immunol; 2021; 12():582594. PubMed ID: 33815356
    [No Abstract]   [Full Text] [Related]  

  • 6. PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.
    Yang Z; Xu J; Li R; Gao Y; He J
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3055-3065. PubMed ID: 31522278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
    Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L
    EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 9. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy.
    Meng QF; Zhao Y; Dong C; Liu L; Pan Y; Lai J; Liu Z; Yu GT; Chen X; Rao L
    Angew Chem Int Ed Engl; 2021 Dec; 60(50):26320-26326. PubMed ID: 34661332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1.
    Cotton AD; Nguyen DP; Gramespacher JA; Seiple IB; Wells JA
    J Am Chem Soc; 2021 Jan; 143(2):593-598. PubMed ID: 33395526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
    Tong B; Wang M
    Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer.
    Xu S; Wang X; Yang Y; Li Y; Wu S
    Cell Death Dis; 2021 Mar; 12(4):282. PubMed ID: 33731702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.
    Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW
    Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
    Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microfluidics-Enabled Nanovesicle Delivers CD47/PD-L1 Antibodies to Enhance Antitumor Immunity and Reduce Immunotoxicity in Lung Adenocarcinoma.
    Su Z; Dong S; Chen Y; Huang T; Qin B; Yang Q; Jiang X; Zou C
    Adv Sci (Weinh); 2023 Jul; 10(20):e2206213. PubMed ID: 37132609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.